Shinichi Oka

Shinichi Oka

Auto-generated profile, based on publicly available information

Shinichi Oka

Japan Institute for Health Security, Tokyo 162-8655, Japan

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in The Lancet
Verified
Journal Article
Closed access
PSPaul E Sax
Paul E Sax
DWDavid Wohl
David Wohl
MYMichael T Yin
Michael T Yin
FPFrank Post
Frank Post
EDEdwin DeJesus
Edwin DeJesus
GTGS-US-292-0104/0111 Study Team
GS-US-292-0104/0111 Study Team

25 February 2009 in Nature
Verified
Journal Article
Closed access
PDF file
YKYuka Kawashima
Yuka Kawashima
KPKatja Pfafferott
Katja Pfafferott
JFJohn Frater
John Frater
PMPhilippa Matthews
Philippa Matthews
RPRebecca Payne
Rebecca Payne
PGPhilip Goulder
Philip Goulder

21 November 2012 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
TGThe Mind Exchange Working Group
The Mind Exchange Working Group
AAAndrea Antinori
Andrea Antinori
GAGabriele Arendt
Gabriele Arendt
IGIgor Grant
Igor Grant
SLScott Letendre
Scott Letendre
ADAlicia Wiercińska Drapato
Alicia Wiercińska Drapato
Many practical clinical questions regarding the management of human immunodeficiency virus (HIV)–associated neurocognitive disorder (HAND) remain unanswered. We sought to identify and develop practical answers to key clinical questions in HAND management. Sixty-six specialists from 30 countries provided input into the program, which was overseen by a steering committee. Fourteen questions were rated as being of greatest clinical importance. Answers were drafted by an expert group based on a comprehensive literature review. Sixty-three experts convened to determine consensus and level of evidence for the answers. Consensus was reached on all answers. For instance, good practice suggests that all HIV patients should be screened for HAND early in disease using standardized tools. Follow-up frequency depends on whether HAND is already present or whether clinical data suggest risk for developing HAND. Worsening neurocognitive impairment may trigger consideration of antiretroviral modification when other causes have been excluded. The Mind Exchange program provides practical guidance in the diagnosis, monitoring, and treatment of HAND.

25 July 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TNTakeshi Nishijima
Takeshi Nishijima
HKHirokazu Komatsu
Hirokazu Komatsu
HGHiroyuki Gatanaga
Hiroyuki Gatanaga
TATakahiro Aoki
Takahiro Aoki
KWKoji Watanabe
Koji Watanabe
SOShinichi Oka
Shinichi Oka
Treatment with tenofovir is sometimes associated with renal dysfunction. Limited information is available on this side effect in patients with small body weight, although the use of tenofovir will spread rapidly in Asia and Africa, where patients are likely to be of smaller body weight. In a single-center cohort, Japanese patients with HIV infection who started tenofovir-containing antiretroviral therapy were retrospectively analyzed. The incidence of tenofovir-associated renal dysfunction, defined as more than 25% decrement of estimated glomerular filtration rate (eGFR) from the baseline, was determined. The effects of small body weight and body mass index (BMI) on tenofovir-associated renal dysfunction, respectively, were estimated in univariate and multivariate Cox hazards models as the primary exposure. Other possible risk factors were evaluated by univariate analysis and those found significant were entered into the multivariate analysis. The median weight of 495 patients was 63 kg. Tenofovir-related renal dysfunction occurred in 97 (19.6%) patients (incidence: 10.5 per 100 person-years). Univariate analysis showed that the incidence of tenofovir-related renal dysfunction was significantly associated with smaller body weight and BMI, respectively (per 5 kg decrement, HR = 1.23; 95% CI, 1.10–1.37; p<0.001)(per 1 kg/m2 decrement, HR = 1.14; 95% CI, 1.05–1.23; p = 0.001). Old age, high baseline eGFR, low serum creatinine, low CD4 count, high HIV viral load, concurrent nephrotoxic drugs, hepatitis C infection, and current smoking were also associated with tenofovir-related renal dysfunction. Multivariate analysis identified small body weight as a significant risk (adjusted HR = 1.13; 95% CI, 1.01–1.27; p = 0.039), while small BMI had marginal significance (adjusted HR = 1.07; 95% CI 1.00–1.16; p = 0.058). The incidence of tenofovir-associated renal dysfunction in Japanese patients was high. Small body weight was identified as an independent risk factor for tenofovir-associated renal dysfunction. Close monitoring of renal function is advocated for patients with small body weight treated with tenofovir.

15 August 2009 in Transplantation
Verified
Journal Article
Closed access
HYHirohisa Yazaki
Hirohisa Yazaki
NGNorihiko Goto
Norihiko Goto
KUKazuharu Uchida
Kazuharu Uchida
TKTakaaki Kobayashi
Takaaki Kobayashi
HGHiroyuki Gatanaga
Hiroyuki Gatanaga
SOShinichi Oka
Shinichi Oka
Background. Prophylaxis against Pneumocystis jiroveci pneumonia (PCP) is only recommended during some periods after renal transplantation. Recent advances in immunosuppressive therapy have considerably reduced acute rejection. However, the reported PCP outbreaks are increasing in renal transplant recipients. Methods. Only three sporadic PCP cases had occurred since 1976 in our Renal Transplant Unit until the index case in July 2004. A PCP outbreak of 27 cases occurred mainly in the outpatient clinic within 1 year, followed by six additional cases during the next 3 years. Molecular analysis of P. jiroveci and surveys of reservoir were performed. Results. Molecular analysis documented that all cases were caused by the same strain. Among 27 cases of the outbreak, human-to-human transmissions were traceable in 22 cases based on dates of outpatient clinic visits and in four cases during hospitalization. Based on the confirmed cases, airborne transmission was suspected with an estimated median PCP incubation period of 53 days (range 7–188 days). Surveys for reservoir of P. jiroveci identified asymptomatic carriers and environmental contamination. Some sporadic cases might be caused by reservoirs. Among the 33 cases, none had received PCP prophylaxis, 22 cases had PCP over 12 months, and six cases over 10 years after renal transplantation. Conclusion. On documentation of a PCP case, we recommend PCP prophylaxis for a maximum period of 6 months (upper limit of incubation period) in all renal transplant recipients including those on regular maintenance immunosuppressive therapy.

1 February 2002 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
SISetsuko Ida
Setsuko Ida
NTNatsuo Tachikawa
Natsuo Tachikawa
ANAya Nakajima
Aya Nakajima
MDManabu Daikoku
Manabu Daikoku
MYMichitami Yano
Michitami Yano
SOShinichi Oka
Shinichi Oka
To assess the possible influence of human immunodeficiency virus type 1 (HIV-1) infection on the clinical course of acute hepatitis A virus (HAV) inf